Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Analysis of von Willebrand Disease in the "Heart of Europe"

I. Vangenechten, P. Smejkal, J. Zavrelova, O. Zapletal, A. Wild, JJ. Michiels, Z. Berneman, J. Blatny, A. Batorova, T. Prigancova, M. Penka, A. Gadisseur

. 2022 ; 6 (4) : e335-e346. [pub] 20221019

Status neindexováno Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031496

Background von Willebrand disease (VWD) is a genetic bleeding disorder caused by defects of von Willebrand factor (VWF), quantitative (type 1 and 3) or qualitative (type 2). The laboratory phenotyping is heterogenic making diagnosis difficult. Objectives Complete laboratory analysis of VWD as an expansion of the previously reported cross-sectional family-based VWD study in the Czech Republic (BRNO-VWD) and Slovakia (BRA-VWD) under the name "Heart of Europe," in order to improve the understanding of laboratory phenotype/genotype correlation. Patients and Methods In total, 227 suspected VWD patients were identified from historical records. Complete laboratory analysis was established using all available assays, including VWF multimers and genetic analysis. Results A total of 191 patients (from 119 families) were confirmed as having VWD. The majority was characterized as a type 1 VWD, followed by type 2. Multimeric patterns concordant with laboratory phenotypes were found in approximately 83% of all cases. A phenotype/genotype correlation was present in 84% (77% type 1, 99% type 2, and 61% type 3) of all patients. Another 45 candidate mutations (23 novel variations), not found in the initial study, could be identified (missense 75% and truncating 24%). An exon 1-3 gene deletion was identified in 14 patients where no mutation was found by direct DNA sequencing, increasing the linkage up to 92%, overall. Conclusion This study provides a cross-sectional overview of the VWD population in a part of Central Europe. It is an addition to the previously published BRNO-VWD study, and provides important data to the International Society of Thrombosis and Haemostasis/European Association for Haemophilia and Allied Disorders VWD mutation database with identification of novel causal mutations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031496
003      
CZ-PrNML
005      
20231027152501.0
007      
ta
008      
230119s2022 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1055/s-0042-1757635 $2 doi
035    __
$a (PubMed)36299619
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Vangenechten, Inge $u Haemostasis Unit, Antwerp University Hospital, Edegem, Belgium $u Medicine and Health Sciences, Haemostasis Research Unit, Antwerp University, Antwerp, Belgium $u Antwerp University, Antwerp, Belgium
245    10
$a Analysis of von Willebrand Disease in the "Heart of Europe" / $c I. Vangenechten, P. Smejkal, J. Zavrelova, O. Zapletal, A. Wild, JJ. Michiels, Z. Berneman, J. Blatny, A. Batorova, T. Prigancova, M. Penka, A. Gadisseur
520    9_
$a Background von Willebrand disease (VWD) is a genetic bleeding disorder caused by defects of von Willebrand factor (VWF), quantitative (type 1 and 3) or qualitative (type 2). The laboratory phenotyping is heterogenic making diagnosis difficult. Objectives Complete laboratory analysis of VWD as an expansion of the previously reported cross-sectional family-based VWD study in the Czech Republic (BRNO-VWD) and Slovakia (BRA-VWD) under the name "Heart of Europe," in order to improve the understanding of laboratory phenotype/genotype correlation. Patients and Methods In total, 227 suspected VWD patients were identified from historical records. Complete laboratory analysis was established using all available assays, including VWF multimers and genetic analysis. Results A total of 191 patients (from 119 families) were confirmed as having VWD. The majority was characterized as a type 1 VWD, followed by type 2. Multimeric patterns concordant with laboratory phenotypes were found in approximately 83% of all cases. A phenotype/genotype correlation was present in 84% (77% type 1, 99% type 2, and 61% type 3) of all patients. Another 45 candidate mutations (23 novel variations), not found in the initial study, could be identified (missense 75% and truncating 24%). An exon 1-3 gene deletion was identified in 14 patients where no mutation was found by direct DNA sequencing, increasing the linkage up to 92%, overall. Conclusion This study provides a cross-sectional overview of the VWD population in a part of Central Europe. It is an addition to the previously published BRNO-VWD study, and provides important data to the International Society of Thrombosis and Haemostasis/European Association for Haemophilia and Allied Disorders VWD mutation database with identification of novel causal mutations.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Smejkal, Petr $u Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic $u Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Zavrelova, Jiri $u Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic $u Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Zapletal, Ondrej $u Department of Pediatric Haematology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Wild, Alexander $u Department of Haematology, University F. D. Roosevelt Hospital, Banská Bystrica, Slovakia
700    1_
$a Michiels, Jan Jacques $u Blood Coagulation and Vascular Medicine Center, Goodheart Institute & Foundation in Nature Medicine, Rotterdam, The Netherlands
700    1_
$a Berneman, Zwi $u Antwerp University, Antwerp, Belgium $u Department of Haematology, Antwerp University Hospital, Edegem, Belgium
700    1_
$a Blatny, Jan $u Department of Pediatric Haematology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Batorova, Angelika $u National Hemophilia Center, Department of Haematology and Blood Transfusion of the Medical School of the Comenius University, Bratislava, Slovakia
700    1_
$a Prigancova, Tatiana $u National Hemophilia Center, Department of Haematology and Blood Transfusion of the Medical School of the Comenius University, Bratislava, Slovakia
700    1_
$a Penka, Miroslav $u Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic $u Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Gadisseur, Alain $u Haemostasis Unit, Antwerp University Hospital, Edegem, Belgium $u Medicine and Health Sciences, Haemostasis Research Unit, Antwerp University, Antwerp, Belgium $u Antwerp University, Antwerp, Belgium $u Department of Haematology, Antwerp University Hospital, Edegem, Belgium
773    0_
$w MED00207997 $t TH open $x 2512-9465 (online) $g Roč. 6, č. 4 (2022), s. e335-e346
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36299619 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20231027152455 $b ABA008
999    __
$a ok $b bmc $g 1889519 $s 1182829
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 6 $c 4 $d e335-e346 $e 20221019 $i 2512-9465 (online) $m TH open $n TH Open $x MED00207997
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Možnosti archivace